Healing & Recovery Protocol
ARA-290 (Cibinetide)Complete dosing & administration guide
A peptide that awakens your body's natural repair system to heal damaged nerves and reduce pain
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Dose Range
4-4mg
Frequency
Once daily
Route
Subcutaneous injection
Cycle Length
Ongoing/indefinite
Dosing
How much
do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Starting Dose
1 mg
Lowest dose tested in the phase 2 sarcoidosis nerve study. A good starting point while watching how the body responds [1].
Standard Dose
4 mg
The 4 mg dose gave the strongest nerve-fiber regrowth and pain relief in the trial — better than the higher 8 mg dose [1][2].
Advanced Dose
8 mg
Highest daily dose studied in the sarcoidosis trial. It was safe but did not beat 4 mg for nerve outcomes [1].
Timing
Best time to take
Administer ARA-290 (Cibinetide) at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
ARA-290 (Cibinetide) injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
ARA-290 (Cibinetide) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
Administration
How do I
use it?
Reconstitution
What you need
- •ARA-290 (Cibinetide) vial (lyophilized powder or solution)
- •Bacteriostatic water or sterile sodium chloride for reconstitution
- •Alcohol swabs for cleaning vial tops and injection sites
- •Appropriately sized syringes with fine-gauge needles (27-30 gauge)
- •Sharps disposal container
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
- •Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
- •Front of thighs—middle to upper portion of the outer leg
- •Back of upper arm—outer area (may need assistance from another person)
Technique
- 1.Wash your hands thoroughly with soap and water before handling supplies
- 2.Clean the injection site with an alcohol swab and let it air dry completely
- 3.Pinch a fold of skin at the chosen injection site
- 4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 5.Inject the medication slowly and steadily over 5-10 seconds
- 6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 7.Rotate injection sites to prevent tissue irritation or lipodystrophy
- 8.Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
ARA-290 is a synthetic innate repair receptor agonist that has completed Phase 2 clinical trials for small fiber neuropathy and is under active development. Animal toxicology studies show a good safety margin with no organ damage or cytotoxicity at doses far exceeding therapeutic levels. Early clinical data from Phase 2 trials demonstrate tolerability with mild injection site reactions and transient headache as primary concerns. However, immunogenicity remains a potential risk with repeated dosing of synthetic peptides, requiring anti-drug antibody monitoring. Long-term safety data beyond 12 weeks does not yet exist.
Evidence comes from preclinical toxicology studies, Phase 1 dose-escalation and safety data, and Phase 2 efficacy trials in small fiber neuropathy patients. The phase 2 trial enrolled 127 patients with a primary endpoint of safety and tolerability. No serious adverse events directly attributable to ARA-290 were reported in early studies. Data suggests good safety at doses up to 1 mg subcutaneously twice weekly, but longer-term outcomes and immunogenicity assessments continue.
Common Side Effects
Experienced by some users
Injection Site Reactions
Redness, mild swelling, or bruising at injection site lasting a few hours to a day
Management: Rotate injection sites, apply ice pack after injection, massage gently to improve absorption
Headache
Mild to moderate headache typically in first few hours after injection
Management: Stay hydrated, rest in a quiet space, over-the-counter pain reliever if needed
Dizziness
Brief dizziness or lightheadedness, especially when standing up quickly
Management: Rise slowly from sitting or lying, avoid sudden movements, inform your doctor if persistent
Less Common
- •Elevated Blood Pressure
- •Fatigue
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with ARA-290 (Cibinetide)
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
ARA-290 (Cibinetide) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓Alpha Lipoic Acid - Enhances antioxidant protection and reduces inflammation to complement nerve regeneration
- ✓Benfotiamine - Fat-soluble form of B1 vitamin that supports nerve function alongside ARA-290's regenerative effects
- ✓Vitamin B12 - Essential for nerve health and myelin formation, works synergistically with nerve repair
With medications
- !Erythropoietin (EPO) - Both activate similar pathways; combining could cause excessive red blood cell production
- !Uncontrolled antihypertensive medications - May cause dangerous blood pressure fluctuations
- !Anticoagulants at high doses - May increase thrombosis risk
With supplements
- ✓Multivitamins - Generally safe to take alongside ARA-290 (Cibinetide). Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Published Research
What the studies show
Brines M, et al. · 2015
ARA-290 treatment resulted in significant improvement of neuropathic pain in diabetic patients along with increased corneal nerve fibers. The peptide showed disease-modifying properties with long-lasting beneficial effects on both pain-related and non-pain-related symptoms.
Culver DA, et al. · 2017
Cibinetide at 4 mg daily significantly increased corneal nerve fiber area by 697 μm², along with increased regenerating intraepidermal fibers. Pain improved significantly in all groups, with changes in nerve fiber abundance correlating with improvements in walking distance and pain severity.
Brines M, et al. · 2018
Corneal nerve fiber area measurements proved useful for tracking therapeutic response to ARA-290 treatment in neuropathy. The metric showed quantifiable changes in nerve morphology and provided superior sensitivity to identify nerve repair compared to skin biopsy.
Liu Y, et al. · 2014
ARA 290 greatly improved recovery from autoimmune nerve inflammation by promoting nerve regeneration and remyelination while suppressing inflammation. The treatment increased protective regulatory T cells and reduced pro-inflammatory immune responses.
van Velzen M, et al. · 2014
ARA 290 treatment was associated with significant improvements in neuropathic pain, increased corneal nerve fibers, improved sensory thresholds, and better quality of life in sarcoidosis patients. The excellent safety profile combined with disease-modifying properties makes it promising for treating this orphan disease.
Heij L, Niesters M, Swartjes M, et al. · 2012
Intravenous ARA 290 at 2 mg three times weekly for 4 weeks improved small fiber neuropathy symptoms versus placebo in sarcoidosis patients.
Head to Head
ARA-290 (Cibinetide) compared
Want the Full Picture?
View the complete ARA-290 (Cibinetide) research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.